Cell Therapy Manufacturing
Streamline Workflows and Reduce Risk through Intentional Activation
Manufacturing success in cell therapy relies on robust cell expansion combined with cost-effective production. Choice of activation method influences cell quality, process complexity, cost of goods, and the ability to scale with confidence. StimulusBio technologies are designed to help teams make intentional, data-informed activation decisions that translate from development into manufacturing‑ready workflows.
Rather than optimizing for expansion alone, balancing performance with operational simplicity reduces rework, minimizes process variability, and preserves optionality as programs advance.
Simplify Activation Workflows for Manufacturing Readiness
Manufacturing teams often inherit activation protocols designed for early research rather than scalable execution. Bead removal steps, repeated cytokine additions, and rigid feeder systems increase hands‑on time and introduce variability.
CellPilot™ Expanders are designed to streamline activation without compromising expansion performance. Bead‑free formats remove downstream cleanup steps, while integrated signal presentation reduces manual intervention during culture. The result is a cleaner handoff from development into manufacturing‑aligned workflows.
- Fewer unit operations and reduced handling
- Lower operator‑to‑operator variability
- Activation workflows that align with closed or semi‑closed systems
- Reduced need for expensive components
Operational Impact Across Manufacturing Workflows
Reducing Cytokine Burden and Cost of Goods Pressure
Cytokines contribute significantly to material costs and process complexity in cell therapy manufacturing. Repeated bolus additions increase reagent usage and introduce opportunities for deviation.
CellPilot™ T Cell CytoExpander integrates cytokine support directly into the activation format, reducing reliance on frequent supplementation. Integrated delivery supports more consistent signaling while helping control reagent consumption and day‑to‑day culture management.
Controlling Phenotype Early to Limit Downstream Re‑Optimization
Phenotype drift discovered late in development often triggers costly re‑optimization cycles. Activation context plays a critical role in shaping cell composition, functional balance, and exhaustion risk.
The tunability of sbPCI™ technology enables early control of activation signals so phenotype decisions are made upstream, where changes are faster and less expensive. Screening‑based configuration allows teams to empirically select activation designs aligned to their target profile before processes are locked.
Accelerating Development Without Sacrificing Translation
Traditional engineered feeder systems and custom APC workflows often require 6–9 months to design, build, and validate, limiting iteration and delaying manufacturing decisions.
High-throughput screening available with CellPilot™ compresses activation configuration into 2–6 weeks through parallel screening of signal designs. Faster iteration enables earlier convergence on manufacturing‑viable conditions while preserving data to support tech transfer and scale‑up.
Design to Support Translation Across Manufacturing Stages
StimulusBio technologies are designed with the full manufacturing lifecycle in mind—from early process development through scale‑up and transfer.
Key design principles include:
- Bead‑free, biocompatible formats compatible with manufacturing workflows
- Defined signaling configurations that support reproducibility
- Activation strategies that can evolve without restarting the platform
These principles help teams move forward with confidence as programs mature and constraints tighten.
The Technology Behind These Applications
Manufacturing simplicity is enabled by sbPCI™ technology which offers unparalleled control of activation and co‑stimulatory signal presentation at the cell surface, without genetic modification.
The same technology supports both workflow‑ready expanders and high-throughput screening‑driven customization that allows teams to match activation strategy to manufacturing needs rather than forcing workflows to adapt later.
How Can You Benefit?
CellPilot‑enabled activation strategies are used by teams who need activation decisions to hold up under manufacturing constraints.
Cell Therapy Developers
Early to Mid-Stage
Move beyond default activation methods and make earlier, more intentional decisions about expansion, phenotype balance, and workflow design. Early clarity reduces the risk of late‑stage rework as programs advance toward scale‑up.
CDMOs
Supporting Multiple Client Programs
Accommodate diverse activation requirements without rebuilding workflows for each program. Screening‑driven configuration and standardized expander formats help balance customization with operational consistency across clients.
Translational Teams
Preparing for Tech Transfer and Scale‑Up
Lock conditions earlier, with clearer linkage between activation design and downstream performance. Earlier convergence supports smoother transfer into manufacturing environments with fewer surprises.